The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to ...

Hepatitis B and C still survive in the dark, driven by a lack of information, unhygienic medical procedures, and poor access ...